SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs strong third-quarter results, especially accelerating AI-compute revenue, sparked analyst upgrades and a bullish response. Traders also debated whether growth justifies the valuation, with heavy capital spending and an approaching share unlock cited as potential risks; Tesla merger discussions remain speculative.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs earnings report beat profit expectations, but softer forward revenue guidance and a reduced advertising outlookalongside slowing growthtriggered a sharp selloff and renewed analyst downgrades. Traders are split between viewing the drop as evidence of tougher competition and weaker growth, and calling it an overreaction that creates a buying opportunity.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary quarterly outlook was sharply raised on strong AI-server demand, with gross-margin expectations also improving, sparking a sharp rally. Traders largely welcomed the update and argued the stock is undervalued, while others questioned whether margins, cash flow and execution can sustain the gains.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention as traders anticipate the 80th-event trigger and final analysis of its Phase 3 REGAL trial of GPS in AML, with recent trading gains fueling speculation about a near-term update and a possible short squeeze. Bullish buyout and positive-data theories are prominent, but skeptics note that no catalyst or outcome is confirmed and the trial results remain uncertain.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

SpaceXs spectrum acquisition and plans to expand Starlink Mobile have fueled concern that it could challenge AT&T and other wireless carriers, contributing to a sharp telecom selloff. Traders debate whether the threat is meaningful or years away, with bulls calling the drop an overreaction and pointing to AT&Ts fiber network and dividend.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention centers on preliminary Phase 1 azer-cel results in progressive multiple sclerosis, with traders viewing the early safety and efficacy signals as a potential pipeline expansion beyond BRIUMVI while emphasizing that the study is small and needs confirmation. BRIUMVIs longer-term and commercial data also feature in the discussion, alongside mixed reactions to the stocks lack of sustained momentum.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

FDA approval of ORLADEYO oral pellets is drawing attention, with traders viewing the easier-to-administer formulation as a possible way to reach more HAE patients and improve tolerability. Some see incremental commercial potential, while others doubt it will meaningfully affect the share price amid continued frustration with BCRXs underperformance and management.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Analyst downgrades citing lackluster October momentum are weighing on Chipotle shares as traders look ahead to earnings amid concerns about slowing sales and margins. The community is split between expecting further declines and viewing the selloff as a buying opportunity.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Speculation about possible U.S. regulatory relief for compounded peptides is a dominant topic, with bullish traders viewing access as a potential growth opportunity and skeptics emphasizing that approval is uncertain. The debate plays out alongside frustration over repeated rallies fading at resistance, while Hims German expansion adds to the growth discussion.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkors strong quarterly results have been overshadowed by a softer-than-expected revenue outlook, alongside a broader semiconductor selloff. Traders are split between viewing the decline as an overreaction to near-term guidance and worrying about AI demand, expansion costs, and whether advanced-packaging growth will justify the investment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ADMA is drawing attention as it approaches and tests its 200-day moving average ahead of earnings, with traders watching for stronger volume and sustained momentum. Optimism about ASCENIV growth and share repurchases is tempered by calls for earnings to validate the outlook and lingering concerns over BIVIGAM weakness and management credibility.

Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing

Adma Biologics (ADMA) closed the most recent trading day at $11.24, moving +1.49% from the previous trading session.

Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?

Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?

Intellia Therapeutics (NTLA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors

In the latest trading session, Adma Biologics (ADMA) closed at $10.33, marking a +1.87% move from the previous day.

ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know  

Recently, Zacks.com users have been paying close attention to Adma Biologics (ADMA). This makes it worthwhile to examine what the stock has in store.

Here's Why Adma Biologics (ADMA) Fell More Than Broader Market

In the most recent trading session, Adma Biologics (ADMA) closed at $10, indicating a -1.24% shift from the previous trading day.

Why Adma Biologics (ADMA) Dipped More Than Broader Market Today

Adma Biologics (ADMA) closed at $9.52 in the latest trading session, marking a -1.86% move from the prior day.

Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?

According to the average brokerage recommendation (ABR), one should invest in Adma Biologics (ADMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know

Adma Biologics (ADMA) closed the most recent trading day at $9.13, moving +2.01% from the previous trading session.

Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know

Adma Biologics (ADMA) reached $9.23 at the closing of the latest trading day, reflecting a -1.7% change compared to its last close.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Tumbles On Slashed Outlook As Short-Seller Aftermath Meets Competitive Headwinds  

Equity

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>Earlier this year, Culper Research alleged channel stuffing and undisclosed related-party transactions at Adma.&nbsp;</li><li>Adma said on Wednesday that there is no evidence of any illegal activity at the company.&nbsp;</li><li>The firm also withdrew its previously issued long-term guidance.</li></ul>ADMA Biologics (ADMA) shares plunged 24% in after-hours trading on Wednesday following the release of disappointing first-quarter results that showed flat revenue and a sharp cut to full-year guidance amid intensifying competition in the U.S. immunoglobulin (IG) market.ADMA reported first-quarter 2026 total revenue of $114.5 million, essentially flat compared with $114.8 million in the year-ago period and well below Wall Street expectations of roughly $140 million.The top-line miss was driven by a steep decline in BIVIGAM sales, which fell 54% year-over-year to $15.4 million, while ASCENIV sales grew 28% to $97.5 million. Both ASCENIV and BIVIGAM are used to treat primary humoral immunodeficiency, a group of inherited disorders leading to low antibody production.Despite the revenue stall, profitability metrics improved markedly. Diluted earnings per share came in at $0.19, above the $0.11 reported in the corresponding quarter of 2025, and in line with Wall Street expectations.<h2 class="st-heading-2">Management Weighs In On Competition</h2>In a statement, President and CEO Adam Grossman acknowledged near-term challenges but emphasized underlying strength in ASCENIV demand.“During the first quarter, the market for U.S. plasma-derived therapies and immunoglobulin experienced increased competitive dynamics which, along with variability in distributor ordering patterns, created near-term topline pressures, particularly impacting BIVIGAM,” Grossman said.“Importantly, these dynamics were limited to distribution and inventory behavior and we believe do not reflect any deterioration in underlying ASCENIV demand, where fundamentals remained strong and continue to improve—with record utilization growth throughout the quarter.”Grossman described Q1 results as a likely “trough revenue baseline” caused by what the company views as a “temporary market dislocation.”<h2 class="st-heading-2">ADMA’s 2026 Guidance</h2>ADMA updated its 2026 financial outlook to reflect the evolving competitive landscape. The company now expects full-year revenue of $530 million to $560 million, down from prior guidance above $635 million, and adjusted core profit of $265 million to $300 million. It also withdrew its previously issued long-term guidance.The company attributed the softer outlook to sustained pricing pressure on standard IG products and changing competitive dynamics.<h2 class="st-heading-2">Short-Seller Report</h2>ADMA also addressed lingering investor concerns stemming from a Culper Research report earlier this year that <a href="https://stocktwits.com/news-articles/markets/equity/adma-stock-drops-after-culper-research-alleges-channel-stuffing/cZ3nq7uRI1i">alleged</a> channel stuffing and undisclosed related-party transactions. Culper alleged in a report that Adma’s reported growth is a “fiction driven more than entirely by a de facto channel stuffing scheme and an undisclosed related party distributor." Without the sales figure inflation, Culper estimated Adma's revenues declined 3% in 2025 as compared to the 20% growth reported.However, Adma said on Wednesday that its Audit Committee, assisted by independent forensic accountants and external counsel, completed a review and “concluded that ADMA has not engaged in any improper channel stuffing or any undisclosed related party transactions,” finding “no evidence of any illegal activity,” it said.<h2 class="st-heading-2">How Did ADMA Retail Traders React?</h2>On Stocktwits, retail sentiment around ADMA stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.A Stocktwits user said that investors who invest now at ‘peak negativity’ stand the chance to make a lot of money.<stembedurl>https://www.stocktwits.com/david999957/message/652525861</stembedurl>Another opined that it is just a “terrible luck” year for the company with the short seller report and market dislocation for Bivigam.<stembedurl>https://www.stocktwits.com/azv134/message/652522379</stembedurl><a href="https://stocktwits.com/symbol/ADMA">ADMA stock</a> has fallen 56% over the past 12 months. &nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/srpt-stock-plunges-after-hours-as-elevidys-demand-slumps-ceo-still-sees-return-to-growth/cZQzkcWReOx">SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ADMA Biologics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

In a statement, President and CEO Adam Grossman acknowledged near-term challenges but emphasized underlying strength in its therapy ASCENIV’s demand.

iShares Core S&P Small-Cap ETF

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$11.23
Prev Close	$11.07
Open	$11.12
Dividend Yield	0.00%
50-Day Moving Average	$9.76
Beta	1.19
Avg. Volume	3M
PE Ratio	15.94

52-Week High	$20.46
52-Week Low	$7.21
Market Capitalization	$2.52B
EPS (Annual)	$0.60
Price to Book	6.20
Revenue Per Employee	$788,520.87

Feed

News

Sentiment

Earnings

Fundamentals

Info

ADMA Fundamentals